Physician profile

Robin A Wright

Internal Medicine · Cincinnati, OH

NPI 1275978868

$1,336.33

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $179.73 2019-2020
Astrazeneca Pharmaceuticals LP $177.33 2019-2020
Novartis Pharmaceuticals Corporation $146.45 2019
Lilly USA, LLC $127.48 2019-2020
Abbvie INC. $98.67 2019
Novo Nordisk INC $95.88 2019-2020
Janssen Pharmaceuticals, INC $93.13 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $79.68 2019
Glaxosmithkline, LLC. $43.28 2019
Kowa Pharmaceuticals America, INC. $39.26 2019
Pfizer INC. $37.75 2019
Ironwood Pharmaceuticals, INC $31.90 2019-2020
Sanofi-Aventis U.S. LLC $30.70 2019
Ucb, INC. $19.75 2019
Sobi, INC $17.58 2019
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $15.88 2020
Ultragenyx Pharmaceutical INC. $15.80 2019
Astellas Pharma US INC $15.06 2019
Sanofi Pasteur INC. $13.47 2019
Scilex Pharmaceuticals INC. $12.69 2019
Allergan, INC. $11.80 2019
Zyla Life Sciences, INC. $11.30 2019
Takeda Pharmaceuticals U.S.A., INC. $10.93 2019
Horizon Therapeutics Plc $10.83 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robin A Wright

$1,336.33

in general payments reported 2019-2025

Years
2019-2020
Top company
Amgen INC.

https://glasscript.com/doctor/542605/robin-a-wright

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.